MCID: TNN002
MIFTS: 39

Tinea Unguium

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Unguium

MalaCards integrated aliases for Tinea Unguium:

Name: Tinea Unguium 12 15 72 33
Cellulitis and Abscess of Upper Arm and Forearm 12
Cellulitis and Abscess of Finger and Toe 12
Cellulitis and Abscess of Gluteal Region 12
Cellulitis and Abscess of Buttock 12
Onychomycosis Due to Dermatophyte 12
Cellulitis and Abscess of Finger 12
Cellulitis and Abscess of Trunk 12
Cellulitis and Abscess of Face 12
Dermatophytic Onychomycosis 12
Dermatophytosis of Nail 12
Cellulitis and Abscess 12
Dermatophytic Onychia 12
Onychomycosis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:13074
ICD9CM 35 681.9
ICD10 33 B35.1
UMLS 72 C0007644 C0040261 C4048550

Summaries for Tinea Unguium

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved.

MalaCards based summary : Tinea Unguium, also known as cellulitis and abscess of upper arm and forearm, is related to tinea pedis and tinea corporis, and has symptoms including thickening of subungueal area An important gene associated with Tinea Unguium is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways is Hfe effect on hepcidin production. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and nail, and related phenotypes are growth/size/body region and mortality/aging

Wikipedia : 75 Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include... more...

Related Diseases for Tinea Unguium

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 tinea pedis 32.0 SQLE ARSI
2 tinea corporis 31.1 SQLE ARSI
3 dermatophytosis 11.2
4 uvulitis 10.5
5 cellulitis 10.4
6 tinea cruris 10.4 SQLE PPIG
7 dermatomycosis 10.4
8 tinea capitis 10.4
9 leprosy 3 10.2
10 nail disorder, nonsyndromic congenital, 10 10.2
11 erythema multiforme 10.2
12 allergic hypersensitivity disease 10.2
13 paronychia 10.2
14 urticaria 10.2
15 keratosis 10.2
16 neuritis 10.2
17 human immunodeficiency virus infectious disease 10.2
18 bullous pemphigoid 10.2
19 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.2
20 hansen's disease 10.2
21 orbital cellulitis 10.2
22 immunodeficiency 17 10.2 STAT1 DDX41
23 tonsillitis 10.1
24 diarrhea 10.1
25 nail disease 10.1
26 48,xyyy 10.1
27 fish allergy 10.1 PPIG DDX41
28 dacryoadenitis 10.1
29 dacryocystitis 10.1
30 hemochromatosis, type 1 10.0 TMPRSS6 HLA-B HFE
31 retinitis pigmentosa, y-linked 9.9 PRDM10 POLB
32 retinal detachment 9.8
33 strabismus 9.8
34 kearns-sayre syndrome 9.8
35 yemenite deaf-blind hypopigmentation syndrome 9.8
36 crohn's colitis 9.8
37 sialadenitis 9.8
38 corneal edema 9.8
39 acute dacryocystitis 9.8
40 branch retinal artery occlusion 9.8
41 central retinal artery occlusion 9.8
42 uveitis 9.8
43 hidradenitis suppurativa 9.8
44 hidradenitis 9.8
45 retinal artery occlusion 9.8
46 impetigo 9.8
47 crohn's disease 9.8
48 chorioretinitis 9.8
49 mechanical strabismus 9.8
50 fasciitis 9.8

Graphical network of the top 20 diseases related to Tinea Unguium:



Diseases related to Tinea Unguium

Symptoms & Phenotypes for Tinea Unguium

Symptoms:

12
  • thickening of subungueal area

MGI Mouse Phenotypes related to Tinea Unguium:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.7 ACOT11 CBSL CNBP HFE OPRM1 POLB
2 mortality/aging MP:0010768 9.4 CBSL CNBP DDX41 HFE OPRM1 POLB

Drugs & Therapeutics for Tinea Unguium

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Efinaconazole Indicated in the treatment of fungal infection of the nail, known as onychomycosis. DB09040
2 Griseofulvin For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by <i>Trichophyton</i> or <i>Microsporum</i> fungi. DB00400
3 Itraconazole For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis. DB01167
4 Tavaborole Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to <i>Trichophyton rubrum</i> or <i>Trichophyton mentagrophytes</i>. DB09041
5 Terbinafine For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch). DB00857

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
4
Amorolfine Approved, Investigational Phase 4 78613-35-1
5
Tavaborole Approved, Investigational Phase 4 174671-46-6
6
carbamide peroxide Approved Phase 4 124-43-6
7
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
8
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
9
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
10
Efinaconazole Approved Phase 4 164650-44-6
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
13 Keratolytic Agents Phase 4
14 Trace Elements Phase 4
15 Micronutrients Phase 4
16 Vitamins Phase 4
17 Folate Phase 4
18 Vitamin B9 Phase 4
19 Nutrients Phase 4
20 Vitamin B3 Phase 4
21 Vitamin B Complex Phase 4
22 Nicotinic Acids Phase 4
23 Pharmaceutical Solutions Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Anti-Bacterial Agents Phase 4
26 Antiparasitic Agents Phase 4
27 Antiprotozoal Agents Phase 4
28 Free Radical Scavengers Phase 4
29 Liposomal amphotericin B Phase 4
30 Antioxidants Phase 4
31 Protective Agents Phase 4
32
Luliconazole Approved Phase 2, Phase 3 187164-19-8
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
35
Econazole Approved Phase 2 27220-47-9 3198
36
Naftifine Approved Phase 2 65472-88-0 73342 47641
37
Aminolevulinic acid Approved Phase 2 106-60-5 137
38
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
41
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
42 Albaconazole Investigational Phase 2 187949-02-6
43 Immunologic Factors Phase 2
44 Immunosuppressive Agents Phase 2
45 Benzonidazole Phase 2
46 Antifungal Agents Phase 2
47 Anti-Infective Agents Phase 2
48 14-alpha Demethylase Inhibitors Phase 2
49 Hormones Phase 2
50 Cytochrome P-450 CYP3A Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
4 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
5 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
6 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
7 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
8 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
9 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
10 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
11 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
12 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
13 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
14 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
15 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
16 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Active, not recruiting NCT03280927 Phase 4 Jublia®
17 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Active, not recruiting NCT02812771 Phase 4 Efinaconazole
18 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
19 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
20 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
21 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
22 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
23 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
24 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
25 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
26 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
27 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
28 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
29 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
30 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
31 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
32 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
33 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
34 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
35 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
36 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Active, not recruiting NCT03168841 Phase 3 Efinaconazole Topical
37 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Not yet recruiting NCT03171584 Phase 3 Terbinafine
38 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
40 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
41 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
44 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
45 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
46 Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium. Completed NCT00253305 Phase 2 Organogel of naftifine, 2%;Organogel of terbinafine, 2%;Organogel of naftifine, 6%;Organogel of terbinafine, 6%
47 An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01484145 Phase 2 Terbinafine HCl
48 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00680160 Phase 2 AN2690
49 A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01080079 Phase 2 Terbinafine Hydrochloride
50 A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety & Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Completed NCT01400594 Phase 2 HTU-520 Patch

Search NIH Clinical Center for Tinea Unguium

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ciclopirox
Ciclopirox olamine
Efinaconazole
Griseofulvin
Itraconazole
Itraconazole
tavaborole
Tavaborole
terbinafine
Terbinafine
Terbinafine hydrochloride

Genetic Tests for Tinea Unguium

Anatomical Context for Tinea Unguium

MalaCards organs/tissues related to Tinea Unguium:

41
Testes, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

19
Nail

Publications for Tinea Unguium

Articles related to Tinea Unguium:

(show top 50) (show all 269)
# Title Authors PMID Year
1
Internal environment of footwear is a risk factor for tinea pedis. 38
31436337 2019
2
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. 38
31353607 2019
3
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 38
31321333 2019
4
Epidemiology of dermatophytic infections between 2008 and 2017 in Barcelona, Spain. 38
31076176 2019
5
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. 38
30768808 2019
6
Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. 38
30747799 2019
7
Detection of Trichophyton rubrum and Trichophyton interdigitale in onychomycosis using monoclonal antibodies against Sub6 (Tri r 2). 38
30152879 2019
8
Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy. 38
30387190 2018
9
Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. 38
30817878 2018
10
Molecular Epidemiological Analysis of the Spreading Conditions of Trichophyton in Long-Term Care Facilities in Japan. 38
30175735 2018
11
Topical efinaconazole: A promising therapeutic medication for tinea unguium. 38
30035311 2018
12
Tinea unguium onychomycosis caused by dermatophytes: a ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. 38
29552686 2018
13
Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. 38
29606407 2018
14
Characterizing the clinical isolates of dermatophytes in Hamadan city, Central west of Iran, using PCR-RLFP method. 38
29439839 2018
15
Subungual Amelanotic Melanoma Masquerading as Onychomycosis. 38
29755903 2018
16
Common Child and Adolescent Cutaneous Infestations and Fungal Infections. 38
29198783 2018
17
Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 38
29849837 2018
18
Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 38
29951161 2018
19
High prevalence of superficial white onychomycosis by Trichophyton interdigitale in a Japanese nursing home with a geriatric hospital. 38
28436564 2017
20
Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. 38
29323069 2017
21
Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). 38
28757272 2017
22
Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. 38
28281037 2017
23
Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. 38
28379097 2017
24
Epidemiological status of dermatophytosis in Guilan, north of Iran. 38
29302626 2017
25
New Antifungal Agents and New Formulations Against Dermatophytes. 38
27502503 2017
26
Tinea Unguium: Diagnosis and Treatment in Practice. 38
27787643 2017
27
Dermatophyte Antigen Kit. 38
28566667 2017
28
[Affinity of Luliconazole for Human Nail Derived Keratin]. 38
29187718 2017
29
Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. 38
28852411 2017
30
Characterization of clinically important dermatophytes in North of Iran using PCR-RFLP on ITS region. 38
27496524 2016
31
[Causative agents of superficial mycoses isolated in Dakar, Senegal: Retrospective study from 2011 to 2015]. 38
27592054 2016
32
[Tinea unguium with Microsporum langeronii and Trichophyton soudanense revealing tinea capitis with M. langeronii]. 38
27592053 2016
33
Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. 38
26992478 2016
34
Is the Dermatophyte Test Strip truly useful for the diagnosis of tinea unguium? Inquiry into "Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes". 38
27910169 2016
35
Production of an anti-dermatophyte monoclonal antibody and its application: immunochromatographic detection of dermatophytes. 38
27250927 2016
36
Identification of three yeast species using the conventional and internal transcribed spacer region sequencing methods as first or second global record from human superficial infections. 38
27392537 2016
37
Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. 38
27659511 2016
38
Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. 38
26886443 2016
39
Epidemiology of Superficial Fungal Infections in Guangdong, Southern China: A Retrospective Study from 2004 to 2014. 38
26883512 2016
40
[Superficial mycoses: casuistry of the Mycology Department of the Instituto Nacional de Higiene "Rafael Rangel", Caracas, Venezuela (2001-2014)]. 38
27382801 2016
41
Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. 38
26369643 2016
42
Development and Evaluation of a Novel Real-Time PCR for Pan-Dermatophyte Detection in Nail Specimens. 38
26412381 2016
43
[Affinity of Luliconazole to Keratin Prepared from Healthy Human Nailand Porcine Hoof]. 38
26936352 2016
44
Computational analysis of conserved coil functional residues in the mitochondrial genomic sequences of dermatophytes. 38
28149055 2016
45
Oral Antifungal Drugs in the Treatment of Dermatomycosis. 38
27251319 2016
46
Epidemiology of Dermatophytoses in Crete, Greece. 38
27904054 2016
47
A survey of the etiological agents of scalp and nail dermatophytosis in Yazd, Iran in 2014-2015. 38
28680997 2015
48
Dermatophytosis in patients with human immunodeficiency virus infection: clinical aspects and etiologic agents. 38
26200786 2015
49
Pattern of Dermatophytes in Patients Attend in Mymensingh Medical College Hospital. 38
26620004 2015
50
Tinea corporis due to Trichophyton violaceum: A report of two cases. 38
26470976 2015

Variations for Tinea Unguium

ClinVar genetic disease variations for Tinea Unguium:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 2:191859910-191859910 2:190995184-190995184

Expression for Tinea Unguium

Search GEO for disease gene expression data for Tinea Unguium.

Pathways for Tinea Unguium

Pathways related to Tinea Unguium according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.47 TMPRSS6 HFE

GO Terms for Tinea Unguium

Cellular components related to Tinea Unguium according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class I protein complex GO:0042612 8.62 HLA-B HFE

Biological processes related to Tinea Unguium according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 8.96 HLA-B HFE
2 cellular response to interferon-beta GO:0035458 8.62 STAT1 DDX41

Sources for Tinea Unguium

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....